CTMX Q2 2025 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M-25.7% YoY

Gross Profit

$19M100.0% margin

Operating Income

-$1M-6.9% margin

Net Income

-$154,000-0.8% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

-63.4%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$175M

Total Liabilities

$55M

Stockholders' Equity

$120M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$25M	-25.7%
Gross Profit	$19M	$25M	-25.7%
Operating Income	-$1M	-$8M	+84.8%
Net Income	-$154,000	-$7M	+97.6%